These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 24120777)

  • 21. Quality of life after primary treatment for localized prostate cancer: long-term considerations.
    Alemozaffar M; Sanda MG
    Eur Urol; 2015 Oct; 68(4):609-10. PubMed ID: 25533419
    [No Abstract]   [Full Text] [Related]  

  • 22. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
    Greiman AK; Keane TE
    Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular disease associated with androgen-deprivation therapy: time to give it due respect.
    Basaria S
    J Clin Oncol; 2015 Apr; 33(11):1232-4. PubMed ID: 25753444
    [No Abstract]   [Full Text] [Related]  

  • 24. Analysis linking UCLA PCI with Expanded Prostate Cancer Index Composite: an evaluation of health related quality of life in Japanese men with localized prostate cancer.
    Namiki S; Takegami M; Kakehi Y; Suzukamo Y; Fukuhara S; Arai Y
    J Urol; 2007 Aug; 178(2):473-7; discussion 477. PubMed ID: 17561164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is hormone ablation still the right choice for advanced prostate cancer?
    Fitzpatrick JM
    BJU Int; 2007 Jul; 100 Suppl 2():36-9. PubMed ID: 17594357
    [No Abstract]   [Full Text] [Related]  

  • 26. Delayed rectal and urinary symptomatology in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation.
    Christie D; Denham J; Steigler A; Lamb D; Turner S; Mameghan H; Joseph D; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Spry NA; Tai KH; Wynne C; Duchesne G; Kovacev O; Francis L; Kramar A; D'Este C; Bill D
    Radiother Oncol; 2005 Nov; 77(2):117-25. PubMed ID: 16271786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Re: does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?
    Griebling TL
    J Urol; 2014 Jun; 191(6):1784-5. PubMed ID: 25280283
    [No Abstract]   [Full Text] [Related]  

  • 28. Post-prostatectomy incontinence during sexual activity: a single center prevalence study.
    Mitchell SA; Jain RK; Laze J; Lepor H
    J Urol; 2011 Sep; 186(3):982-5. PubMed ID: 21791358
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Urinary and sexual disorders following localised prostate cancer management].
    Haab F; Beley S; Cornu JN; Culine S; Cussenot O; Hennequin C
    Bull Cancer; 2010 Dec; 97(12):1537-49. PubMed ID: 21220229
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
    Cui Y; Zong H; Yan H; Li N; Zhang Y
    Urol Int; 2014; 93(2):152-9. PubMed ID: 24603064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of exercise studies in prostate cancer survivors receiving androgen deprivation therapy calls for an aggressive research agenda to generate high-quality evidence and guidance for exercise as standard of care.
    Winters-Stone KM; Beer TM
    J Clin Oncol; 2014 Aug; 32(23):2518-9. PubMed ID: 25002711
    [No Abstract]   [Full Text] [Related]  

  • 32. Androgen deprivation therapy in prostate cancer: looking beyond prostate-specific antigen and testosterone levels.
    Saad F
    Eur Urol; 2015 May; 67(5):837-8. PubMed ID: 25168615
    [No Abstract]   [Full Text] [Related]  

  • 33. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. More should be done to prevent the harmful effects of long-term androgen ablation therapy in prostate cancer.
    Barrass BJ; Thurairaja R; Persad RA
    BJU Int; 2004 Jun; 93(9):1175-6. PubMed ID: 15180599
    [No Abstract]   [Full Text] [Related]  

  • 35. Prostate cancer and the therapeutic benefits of structured exercise.
    Parsons JK
    J Clin Oncol; 2014 Feb; 32(4):271-2. PubMed ID: 24344219
    [No Abstract]   [Full Text] [Related]  

  • 36. How should continence and incontinence after radical prostatectomy be evaluated? A prospective study of patient ratings and changes with time.
    Holm HV; Fosså SD; Hedlund H; Schultz A; Dahl AA
    J Urol; 2014 Oct; 192(4):1155-61. PubMed ID: 24727062
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of prostate cancer].
    Romics I
    Orv Hetil; 2010 Apr; 151(14):580-3. PubMed ID: 20332076
    [No Abstract]   [Full Text] [Related]  

  • 38. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer.
    Wei JT; Dunn RL; Sandler HM; McLaughlin PW; Montie JE; Litwin MS; Nyquist L; Sanda MG
    J Clin Oncol; 2002 Jan; 20(2):557-66. PubMed ID: 11786586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Work ability in prostate cancer survivors after radical prostatectomy.
    Dahl S; Cvancarova M; Dahl AA; Fosså SD
    Scand J Urol; 2016; 50(2):116-22. PubMed ID: 26609896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate operations: long-term effects on sexual and urinary function and quality of life. Comparison with an age-matched control population.
    Deliveliotis C; Liakouras C; Delis A; Skolarikos A; Varkarakis J; Protogerou V
    Urol Res; 2004 Aug; 32(4):283-9. PubMed ID: 15057494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.